Hipertrofik Kardiyomiyopati

Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:372–389.

Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–1254.

Maron MS, Hellawell JL, Lucove JC, et al. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J Cardiol. 2016;117:1651–1654.

Basavarajaiah S, Wilson H, Whyte G et al. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance top re-participation screening. J Am Coll Cardiol, 2008;51:1033-9.

Haykal M, Matsumori A, Saleh A, et al. Diagnosis and treatment of HCV heart diseases. Expert Rev Cardiovasc Ther. 2021;19(6):493-499. doi:10.1080/14779072.2021.1917383.

Menon SC, Eidem BW, Dearani JA et al. Diastolic dysfunction and its histopathological correlation in obstructive hypertrophic cardiomyopathy in children and adolescents. J Am Soc Echocardiogr, 2009;22:1327-34.

Baxi AJ, Restrepo CS, Vargas D et-al. Hypertrophic Cardiomyopathy from A to Z: Genetics, Pathophysiology, Imaging, and Management. Radiographics. 2016;36 (2): 335-54.

Yamaguchi H, Ishimura T, Nishiyama S et al. Hypertrophic Nonobstructive Cardiomyopathy with Giant Negative T Waves (Apical Hypertrophy): Ventriculographic and Echocardiographic Features in 30 Patients. Am J Cardiol. 1979;44(3):401-12.

Hughes R, Knott K, Malcolmson J et al. Apical Hypertrophic Cardiomyopathy: The Variant Less Known. J Am Heart Assoc. 2020;9(5):e015294.

Dillman J, Mueller G, Attili A, Dorfman A, Ensing G, Gordon D. Case 153: Atypical Tumefactive Hypertrophic Cardiomyopathy. Radiology. 2010;254(1):310-313.

Anwar AM, tenCate FJ. Echocardiographic evaluation of hypertrophic cardiomyopathy: a review of up-to-date knowledge and practical tips. Echocardiography. 2021;38:1795–808. 10.1111/echo.15200.

Anwar MA. Mitral regurgitation in hypertrophic cardiomyopathy: a narrative review of mechanism and current management. Int J Clin Cardiol. 2022;9:248.

Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124:40–47.

Groarke JD, Galazka PZ, Cirino AL, et al. Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers. Eur Heart J Cardiovasc Imaging. 2018;19:1109–1116.

Fumagalli C, Zocchi C, Ciabatti M, et al. From atrial fibrillation management to atrial myopathy assessment: The evolving concept of left atrium disease in hypertrophic cardiomyopathy. Can J Cardiol. 2024;40(5):876-886.

Ding W, Bhushan S, Ma C, Yan Y, Xiao Z. Right ventricle involvement in hypertrophic cardiomyopathy and role of cardiac magnetic resonance in hypertrophic cardiomyopathy: Review Article. Heart Surg Forum. 2021;24(4):E746-E750.

Basso C, Michaud K, d'Amati G, et al; Association for European Cardiovascular Pathology. Cardiac hypertrophy at autopsy. Virchows Arch. 2021;479(1):79-94.

Musat D, Sherrid MV. Pathophysiology of hypertrop-hic cardiomyopathy determines its medical treat-ment. Anadolu Kardiyol Derg, 2006;6(Suppl 2):9-17.

Memmola C, Iliceto S, Napoli VF et al. Coronary flow dynamics and reserve assessed by transesophageal echocardigraphy in obstructive hypertrophic cardi-omyopathy. Am J Cardiol, 1994;74:1147-1151.

Baxi AJ, Restrepo CS, Vargas D et-al. Hypertrophic Cardiomyopathy from A to Z: Genetics, Pathophysiology, Imaging, and Management. Radiographics. 2016;36 (2): 335-354.

Birincioğlu CL. Hipertrofik kardiyomiyopati. T Klin Kardiyoloji 2003;16:14-34.

Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation 2008;117;429-439.

Marszalek RJ, John Solaro R, Wolska BM. Coronary arterial vasculature in the pathophysiology of hypertrophic cardiomyopathy. Pflugers Arch. 2019;471(5):769-780.

Díez-López C, Salazar-Mendiguchía J. Clinical presentations of hypertrophic cardiomyopathy and implications for therapy. Glob Cardiol Sci Pract. 2018;2018(3):19.

Dominguez-Rodriguez A, Thibodeau JT, Ayers CR, et al. Impact of bendopnea on postoperative outcomes in patients with severe aortic stenosis undergoing aortic valve replacement. Interact Cardiovasc Thorac Surg. 2018;27(6):808-812.

Avrupa Kardiyoloji Derneği (ESC) Senkop Tanı ve Tedavi Görev Grubu. Senkop tanı ve tedavi kılavuzu. Türk Kardiyol Dern Arş 2009;Suppl 8.

Zipes DP, Camm AJ, Borggrefe M et al. American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/ AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8:746-837.

Spirito P, Bellone P, Harris KM et al. Magnitude of left ventricular hypertrophy predicts sudden death in hypertrophic cardiomyopathy. N Eng J Med 2000;342:1778-1785.

Maron BJ, Shen WK, Link MS, et al. Efficiancy of implantable cardioverter-defibrillators for preventions of sudden death in patients with hypertrophic cardi-omyopathy. N Eng J Med, 2000;342:365-373.

Canepa M, Fumagalli C, Tini G, et al; SHaRe Investigators. Temporal trend of age at diagnosis in hypertrophic cardiomyopathy: An analysis of the international Sarcomeric Human Cardiomyopathy Registry. Circ Heart Fail. 2020;13(9):e007230.

Guttmann OP, Rahman MS, O’Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100:465–472. doi: 10.1136/heartjnl-2013-304276.

Rowin EJ1, Hausvater A2, Link MS2, Abt P. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2017;136(25):2420–2436.

Rowin EJ, Link MS, Maron MS, Maron BJ. Evolving contemporary management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2023;148(22):1797-1811.

Dominguez F, Ramos A, Bouza E, et al. Infective endocarditis in hypertrophic cardiomyopathy: A multicenter, prospective, cohort study. Medicine (Baltimore). 2016;95(26):e4008.

Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. JACC Heart Fail. 2018;6(5):353-363.

Kwon DH, Setser RM, Popovic ZB et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyo-pathy: A delayed contrast enhanced MRI study. Int J Cardiovasc Imaging 2008;24:617-25.

Bernardini A, Crotti L, Olivotto I, Cecchi F. Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy. Eur Heart J Suppl. 2023;25(Suppl C):C173-C178.

Weinsaft JW, Kim HW, Crowley AL, et al. LV thrombus detection by routine echocardiography: insights into performance characteristics using delayed enhancement CMR. JACC Cardiovasc Imaging 2011;4:702–712.

Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009;53:284–291. https://doi.org/10.1016/j.jacc.2008.08.064.

Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2024;150(8):e198.

Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29(2):270-276.

McKenna WJ, Spirito P, Desnos M et al. Experience from clinical genetics in hypertrophic cardiomyo-pathy: Proposal for new diagnostic criteria in adult members of affected families. Heart, 1997;77:130-132.

Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251-1258.

Toepfer CN, Garfinkel AC, Venturini G, et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation 2020;141:828-842.

Chuang C, Collibee S, Ashcraft L, et al. Discovery of Aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem 2021;64:14142-14152.

Wasfy JH, Walton SM, Beinfeld M, et al. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value; final evidence report and meeting summary: Institute for Clinical and Economic Review; 2021 November 16, 2021.

Mateo JJS, Gimeno JR. Alcohol septal ablation in hypertrophic cardiomyopathy. Glob Cardiol Sci Pract 2018;2018:30.

Alam M, Dokainish H, Lakkis N. Alcohol septal abla-tion for hypertrophic obstructive cardiomyopathy: A systematic review of published studies. J Interv Cardiol, 2006;19:319-327.

Ralph-Edwards A, Woo A, McCrindle BW et al. Hypertrophic obstructive cardiomyopathy: Comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 2005;129:351-358.

Özer T, Elveran A, Doğan C, et al. Comparison of septal myectomy and transcoronary septal alcohol ablation in patients with hypertrophic obstructive cardiomyopathy. Cardiovasc Surg Int 2020;7(3):152-156.

Zhou M, Ta S, Hahn RT, et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy. JAMA Cardiol. 2022 May 1;7(5):529-538.

Galve E, Sambola A, Saldaña G, et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. Heart. 2010;96(5):352–356.

Subramanian M, Shekar V, Krishnamurthy P, et al. Optimizing diastolic filling by pacing in nonobstructive hypertrophic cardiomyopathy. Heart Rhythm. 2023;20(9):1307–1313.

Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: Technique and hemodynamic results of subaortic ventriculomyotomy. Ann Surg 1961;154:181-187.

Erentug V, Bozbuga N, Kırali K, et al. Surgical treatment of subaortic obstruction in adolescent and adults: Long-term fallow. J Cardiac Surg 2005;20:16-21.

Morrow AG. Hypertrophic subaortic stenosis. Operative methods utilized to relieve left ventricular outflow obstruction. J ThoracCardiovasc Surg 1978;76:423-30.

Musharbash FN, Schill MR, Hansalia VH, Schuessler RB, Leidenfrost JE, Melby SJ, Damiano RJ Jr. Minimally Invasive Versus Full-Sternotomy Septal Myectomy for Hypertrophic Cardiomyopathy. Innovations (Phila). 2018 Jul/Aug;13(4):261-266.

Ozgur MM, Hancer H, Gurel B, Altas O, Bulut HI, Bas T, Sarikaya S, Kırali K. Upper reversed-T mini-sternotomy for sutureless aortic valve replacement: an alternative for high-risk patients. Cardiovasc J Afr 2025;36:196-201.

Ozgur MM, Hancer H, Yigit F, Aksut M, Ozer T, Altas O, Sarıkaya S, Kırali K. Reverse-U Aortotomy (Kırali Incision) for Aortic Valvular Interventions. Thorac Cardiovasc Surg. 2025;73(2):126-131.

Yakut C, Kırali K. Aort kapak hastalıklarında cerrahi değerlendirme ve cerrahi yaklaşımlar. Türkiye Klinik Kardiyol 2002;15:111-35.

Sun D, Schaff HV, Nishimura RA, Geske JB, Dearani JA, Ommen SR. Transapical septal myectomy for hypertrophic cardiomyopathy with midventricular obstruction. Ann Thorac Surg. 2021;111(3):836-844.

Hang D, Schaff HV, Ommen SR, Dearani JA, Nishimura RA. Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2018;155(5):2096-2102.

Kayalar N, Schaff HV, Daly RC, Dearani JA, Park SJ. Concomitant septal myectomy at the time of aortic valve replacement for severe aortic stenosis. Ann Thorac Surg 2010;89:459-64.

Mohr R, Schaff HV, Danielson GK et al. The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy. Experience over 15 years. J Thorac Cardiovasc Surg 1989;97:666-674.

Brown ML, Schaff HV, Dearani JA, Li Z, Nishimura RA, Ommen SR. Relationship between left ventricular mass, wall thickness, and survival after subaortic septal myectomy for hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg. 2011;141(2):439-443.

Mataracı İ, Polat A, Songur ÇM ve ark. Hipertrofik obstrüktif kardiyomiyopatide cerrahi tedavi ve sonuçları. Türk Göğüs Kalp Damar Cer Derg 2009;17:243-248.

Balaram SK, Swistel D. Long-term prognosis of hypertrophic cardiomyopathy after surgery. Anadolu Kardiyol Derg 2006;6(Suppl 2):37-39.

Brown PS, Robert CS, McIntosh CL, Clark RE. Aortic regurgitation after left ventricular myotomy and myectomy. Ann Thorac Surg 1991;51:585-592.

Sherrid MV, Chaudhry FA, Swistel DG. Obstructive hypertrophic cardiomyopathy: Echocardiography, pat-hophysiology, and the continuing evolution of surgery for obstruction. Ann Thorac Surg 2003;75:620-632.

Erentug V, Bozbuga N, Eren E ve ark. Hipertrofik kardiyomyopatide cerrahi tedavi. Türk Göğüs Kalp Damar Cer Derg 2004;12:94-97.

McIntosh CL, Greenburg GH, Maron BJ, et al. Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardi-omyopathy. Ann Thorac Surg, 1989;47:236-246.

Klues HG, Roberts WC, Maron BJ. Anormalous inser-tion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: Significance in producing left ventricular outflow obstruction. Circulation 1991;84:1188-1197.

McINtosh CL, Maron BJ, Cannon RO, et al. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation 1992;86:60-67.

Wan CKN, Dearani JA, Sundt III TM, Ommen SR, Schaff HV. What is the best surgical treatment for obstructive hypertrophic cardiomyopathy and dege-nerative mitral regurgitation. Ann Thorac Surg 2009;88:727-732.